View in EDS

Antitumor activity of ipilimumab or BRAF ± MEK inhibition after pembrolizumab treatment in patients with advanced melanoma: analysis from KEYNOTE-006.

Saved in:
Bibliographic Details
Title: Antitumor activity of ipilimumab or BRAF ± MEK inhibition after pembrolizumab treatment in patients with advanced melanoma: analysis from KEYNOTE-006.
Authors: Long, G.V.1,2,3,4 (AUTHOR) georgina.long@sydney.edu.au, Arance, A.5 (AUTHOR), Mortier, L.6 (AUTHOR), Lorigan, P.7,8 (AUTHOR), Blank, C.9 (AUTHOR), Mohr, P.10 (AUTHOR), Schachter, J.11 (AUTHOR), Grob, J.-J.12 (AUTHOR), Lotem, M.13 (AUTHOR), Middleton, M.R.14 (AUTHOR), Neyns, B.15 (AUTHOR), Steven, N.16 (AUTHOR), Ribas, A.17 (AUTHOR), Walpole, E.18,19 (AUTHOR), Carlino, M.S.1,20 (AUTHOR), Lebbe, C.21 (AUTHOR), Sznol, M.22 (AUTHOR), Jensen, E.23 (AUTHOR), Leiby, M.A.23 (AUTHOR), Ibrahim, N.23 (AUTHOR)
Source: Annals of Oncology. Feb2022, Vol. 33 Issue 2, p204-215. 12p.
Database: Academic Search Ultimate
Description
ISSN:09237534
DOI:10.1016/j.annonc.2021.10.010